Stockreport

Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failur...

Lantern Pharma Inc.  (LTRN) 
PDF Lantern Pharma Schedules Type C Meeting with the FDA to Advance HARMONIC™ Protocol Amendments Targeting This High-Need Population, Reflecting LP-300’s Novel Mechanism of [Read more]